1)Stangier J, Rathgen K, Stähle H, et al:The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292-303,2007
2)Gosselin RC, Adcock DM, Douxfils J:An update on laboratory assessment for direct oral anticoagulants (DOACs). Int J Lab Hematol 41(Suppl1):33-39,2019
3)Douxfils J, Ageno W, Samama CM, et al:Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 16:209-219,2018
4)Samuelson BT, Cuker A, Siegal DM, et al:Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest 151:127-138,2017
5)Connors JM:Testing and monitoring direct oral anticoagulants. Blood 132:2009-2015,2018
6)Exner T, Michalopoulos N, Pearce J, et al:Simple method for removing DOACs from plasma samples. Thromb Res 163:117-122,2018
7)門平靖子,森下英理子:DOAC療法が先天性血栓性素因に及ぼす影響.日血栓止血会誌 29:20-27,2018
8)Tripodi A, Cohen H, Devreese KMJ:Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 18:1569-1575,2020
9)Platton S, Hunt C:Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban. Int J Lab Hematol 41:227-233,2019